China Biotech (01177.HK): TQF3250 Capsule "GLP-1 Receptor Agonist" Clinical Trial Application Accepted by NMPA.

Finance APP News, China Biopharmaceuticals (01177.HK) announced that the new drug clinical trial application (IND) for the national first-class innovative drug TQF3250 capsule "GLP-1 receptor agonist (GLP-1RA)" independently developed by the group has been accepted by the National Medical Products Administration of China (NMPA) and is intended for the treatment of type 2 diabetes.